Expert Columns & Interviews

CROI '07 -- Dyslipidemia : An Expert Interview With Judith A. Aberg, MD Metabolic effects leading to dyslipidemia, lipoatrophy, and cardiac disease continue to be the subject of research studies. The results and interpretation of these studies may be surprising.
Experts And Viewpoints, April 26, 2007
ICAAC 2006: Pharmacogenomics--An Expert Interview With Princy Kumar, MD Women and people of color are "the new faces of AIDS." What do we know about the effects of gender and race on responses to antiretroviral therapy?
Experts And Viewpoints, October 17, 2006
Expert Interview With Dr. Andrew Carr Dr. Carr discusses metabolic syndrome in persons with HIV, predictors of lipoatrophy, renal monitoring, abacavir HSR, and more.
Experts And Viewpoints, October 11, 2006
New CDC HIV Screening Recommendations: Interview w/ Dr. Rochelle Walensky A expert on HIV epidemiology and HIV screening procedures shares her insights regarding the CDC's new, ground-breaking HIV testing recommendations.
Experts And Viewpoints, October 02, 2006
An Expert Interview With Dr. Cal Cohen Recent approvals of new HIV drugs and a rich antiretroviral drug development pipeline have created great optimism among both clinicians and patients. A leader in the field explains the latest data.
Experts And Viewpoints, August 29, 2006
An Expert Interview With Dr. Douglas Ward Boosted PIs are a mainstay of antiretroviral therapy, and new data on existing and investigational PIs continue to emerge. An expert clinician reports new data and explains the clinical significance.
Experts And Viewpoints, August 29, 2006
An Expert Interview With Dr. David D. Ho Understanding of the pathogenesis of HIV disease made a quantum leap forward with the seminal research by this HIV expert. What does Dr. Ho see for the future of HIV treatment?
Experts And Viewpoints, May 22, 2006
An Expert Interview With Dr. Martin S. Hirsch Dr. Martin Hirsch discusses unresolved issues in antiretroviral therapy for HIV: When is the best time to start treatment? Do therapy interruptions work? Does IL-2 have a place in treatment?
Experts And Viewpoints, May 18, 2006
Antiretrovirals for Highly Experienced Patients: Dr. Eric Daar How to individualize HIV treatment in this hard-to-treat population? How should clinicians optimize the use of the newest agents? This HIV expert explains key strategies and important emerging data.
Experts And Viewpoints, May 15, 2006
New STI Strategies: Expert Interview With Dr. Roy Gulick Is it time to take another look at strategies to minimize exposure to antiretroviral drugs? Dr. Gulick reviews and evaluates new data from CROI 2006 in this interview with Medscape.
Experts And Viewpoints, March 10, 2006
ARV Pharmacology: Expert Interview With Dr. Courtney V. Fletcher From CROI 2006: Studies of clinical pharmacology of antiretrovirals have an essential role in the overall care of patients with HIV and development of new agents. Learn the latest here.
Experts And Viewpoints, March 06, 2006
HAART, Dyslipidemia, and CV Risk: Interview With Dr. McComsey Metabolic abnormalities associated with HIV and its treatment have emerged as one of the most vexing challenges in HIV management. Read one expert's perspective on relevant CROI data.
Experts And Viewpoints, February 15, 2006
Emerging ART Options: Expert Interview With Paul Sax, MD From CROI 2006: A leading HIV expert discusses new antiretroviral agents and coformulated therapies, as well as novel compounds under investigation for the management of HIV infection.
Experts And Viewpoints, February 15, 2006
Fine-Tuning ART Strategies: Expert Interview W/ Calvin Cohen, MD Dr. Calvin Cohen discusses data from the 2005 European AIDS Conference -- regimen simplification, NRTI-sparing tx, bone density/lipodystrophy, comparison of commercial phenotypic tests, and more.
Experts And Viewpoints, December 01, 2005
Methamphetamine: Important Clinical Guidance for HCWs Twelve million Americans used meth in 2003. What are the public health implications, as well as potential consequences for individual users?
Experts And Viewpoints, October 17, 2005
Efficacy vs Tolerability for Experienced Patients: Dr. Ian Sanne IAS 2005: Negotiating the right course between safety & efficacy, particularly for experienced patients, requires skill. Learn more from a clinical expert who practices in a resource-limited setting.
Experts And Viewpoints, August 16, 2005
HIV/Hepatitis Coinfection: Interview With Dr. Paula Greiger From IAS 2005: Management of HIV and hepatitis virus coinfection requires particular knowledge and skill, and an increasing number of coinfected patients require this specialized care.
Experts And Viewpoints, August 09, 2005
ART for Drug-Naive Patients: Expert Interview With Dr. Cal Cohen Better-tolerated, simple regimens are now the rule for most ART-naive patients, but clinicians and patients must still weigh a number of critical considerations prior to treatment initiation.
Experts And Viewpoints, August 05, 2005
ART Drug Resistance: Interview With Dr. Jonathan Schapiro Antiretroviral drug resistance continues to be one of the most significant challenges confronting both clinicians and patients. Learn more about recent data from the 2005 HIV Drug Resistance Workshop.
Experts And Viewpoints, July 07, 2005
HIV Superinfection: What Clinicians and Patients Should Know Ongoing research has begun to offer some answers about this hotly debated area of HIV research and care.
Experts And Viewpoints, June 09, 2005

No Results